Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brilliant-001
PACTR202502617314127Phase 1Not yet recruiting
- Sponsor
- South African Medical Research Council
- Start
- Dec 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of BG505 SOSIP GT1.1 gp140, 426c.Mod.Core-C4b, 3M-052-AF and aluminium hydroxide in human immunodeficiency virus infection (HIV), sponsored by South African Medical Research Council. Primary endpoints: Safety and tolerability, Env-specific binding antibody responses and 1 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
BG505 SOSIP GT1.1 gp140426c.Mod.Core-C4b3M-052-AFaluminium hydroxide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202502617314127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202502617314127.